Canagliflozin for Japanese patients with chronic heart failure and type II diabetes

Abstract

BackgroundReports that sodium glucose cotransporter 2 inhibitors decrease cardiovascular death and events in patients with diabetes have attracted attention in the cardiology field. We conducted a study of canagliflozin in patients with chronic heart failure and type II diabetes.MethodsThirty-five Japanese patients with chronic heart failure and type II diabetes were treated with canagliflozin for 12\xa0months. The primary endpoints were the changes of subcutaneous, visceral, and total fat areas at 12\xa0months determined by computed tomography. Secondary endpoints included markers of glycemic control, renal function, and oxidative stress, as well as lipid parameters, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), flow-mediated dilation (FMD), and echocardiographic left ventricular function.ResultsAll fat areas (subcutaneous, visceral, and total) showed a significant decrease at 12\xa0months. ANP and BNP also decreased significantly, along with improvement of renal function, oxidized LDL, and E/e′, FMD increased significantly after canagliflozin treatment.ConclusionCanagliflozin demonstrated cardiac and renal protective effects as well as improving oxidative stress, diastolic function, and endothelial function. This drug was effective in patients who had heart failure with preserved ejection fraction and could become first-line therapy for such patients with diabetes.Trial registration UMIN (http://www.umin.ac.jp/), Study ID: UMIN000021239